Abstract
The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.
Keywords: Alzheimer’s disease, clinical course, cohort study, dementia, europe, geographical variation, cognitive, functional, NPI, caregiver burden, hospital admission
Current Alzheimer Research
Title:Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Volume: 9 Issue: 8
Author(s): A. Salva, M.O. Rikkert, M. Tsolaki, P.-J. Ousset, F. Pasquier, J.M. Ribera-Casado, A.S. Rigaud, P. Robert, G. Rodriguez, E. Salmon, P. Martinez-Lage, P. Scheltens, A. Schneider, A. Sinclair, L. Spiru, J. Touchon, D. Zekry, B. Winblad, S. Andrieu, M. Boada, L. Hausner, L. Frolich, C. Cantet, V. Gardette, E. Reynish, S. Gillette, E. Aguera-Morales, S. Auriacombe, B. Vellas, R. Bullock, J. Byrne, V. Camus, A. Cherubini, M. Eriksdotter-Jonhagen, G.B. Frisoni, S. Hasselbalch and R.W. Jones
Affiliation:
Keywords: Alzheimer’s disease, clinical course, cohort study, dementia, europe, geographical variation, cognitive, functional, NPI, caregiver burden, hospital admission
Abstract: The clinical progression of Alzheimer disease (AD) was studied in European subjects under treatment with AChE inhibitors (AChE-I) in relation to geographical location over a 2-years period. One thousand three hundred and six subjects from 11 European countries were clustered into 3 regions (North, South, West) and investigated with biannual follow-up over 2 years. Primary outcomes were cognitive, functional and behavioral measures. Caregiver burden, hospital admission and admission to nursing home were also recorded. Participant cognitive function declined non-linearly over time (MMSE: -1.5 pts/first year, -2.5 pts/second year; ADAScog: + 3.5 pts/first year, + 4.8 pts/second year), while the progression of behavioral disturbances (NPI scale) was linear. Neither scale showed regional differences, and progression of the disease was similar across Europe despite different health care systems. Functional decline (ADL, IADL) tended to progress more rapidly in Southern Europe (p=0.09), while progression of caregiver burden (Zarit Burden Interview) was most rapid in Northern Europe (5.6 pts/y, p=0.04). Incidences of hospital admission (10.44, 95%CI: 8.13-12.75, p<0.001) and admission to nursing home (2.97, 95%CI: 1.83-4.11, p<0.001) were lowest in Southern Europe. In general cognitive and functional decline was slower than in former cohorts. European geographical location reflecting differences in culture and in health care system does not impact on the progression of AD but does influence the management of AD subjects and caregiver burden.
Export Options
About this article
Cite this article as:
Salva A., Rikkert M.O., Tsolaki M., Ousset P.-J., Pasquier F., Ribera-Casado J.M., Rigaud A.S., Robert P., Rodriguez G., Salmon E., Martinez-Lage P., Scheltens P., Schneider A., Sinclair A., Spiru L., Touchon J., Zekry D., Winblad B., Andrieu S., Boada M., Hausner L., Frolich L., Cantet C., Gardette V., Reynish E., Gillette S., Aguera-Morales E., Auriacombe S., Vellas B., Bullock R., Byrne J., Camus V., Cherubini A., Eriksdotter-Jonhagen M., Frisoni G.B., Hasselbalch S. and Jones R.W., Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251066
DOI https://dx.doi.org/10.2174/156720512803251066 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis
Current Neuropharmacology Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) HIV Genes Diversify in B Cells
Current HIV Research Reduced Alzheimer’s Disease Pathology by St. John’s Wort Treatment is Independent of Hyperforin and Facilitated by ABCC1 and Microglia Activation in Mice
Current Alzheimer Research Patent Selections:
Recent Patents on Regenerative Medicine Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis?
Current Genomics α-Synuclein- and MPTP-Generated Rodent Models of Parkinsons Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach
CNS & Neurological Disorders - Drug Targets Functional and Structural Benefits Induced by Omega-3 Polyunsaturated Fatty Acids During Aging
Current Neuropharmacology Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) Patenting Penicillium Strains
Recent Patents on Biotechnology Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research Uncoupling Protein-2 and the Potential Link Between Metabolism and Longevity
Current Aging Science Estrogen Receptors: Mechanism of Action and Relevance to Schizophrenia
Current Psychiatry Reviews The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale
Current Alzheimer Research Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II B)
Current Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine